Oral bioavailability of sulphonamides in ruminants: a comparison between sulphamethoxazole, sulphatroxazole, and sulphamerazine, using the dwarf goat as animal model.
The various sulphonamides show marked differences in disposition characteristics after administration to ruminants. For use in combination with a diaminopyrimidine derivative such as trimethoprim or baquiloprim, it is essential that a sulphonamide has similar pharmacokinetic properties in order to obtain optimal synergy. In the present study the pharmacokinetics of sulphamethoxazole, sulphatroxazole, and sulphamerazine were investigated in dwarf goats (n = 6) after IV and intraruminal administration at a dose of 30 mg/kg bodyweight. In addition, the in vitro binding of sulphamerazine to ruminal contents was studied as a possible explanation for a reduced absorption rate. Sulphamethoxazole showed the most rapid absorption after intraruminal administration (mean tmax +/- SD : 0.8 +/- 0.2h). However, the drug was rapidly eliminated from the plasma (t1/2 beta : 2.4 +/- 1.5 h) and the bioavailability was only 12.4 +/- 4.7%, most likely due to an extensive 'first-pass' effect. The bioavailability of orally administered sulphamerazine and sulphatroxazole was much higher (67.6 +/- 13.5% and 70.2 +/- 32.3%, respectively). After intraruminal administration, sulphatroxazole showed the highest plasma peak concentration (26.1 +/- 6.3 mg/l) and the longest plasma half-life (4.7 +/- 1.8h) and mean residence time (13.9 +/- 4.5 h). Sulphamerazine showed considerable binding to rumen contents in vitro. Based on its pharmacokinetic properties sulphatroxazole appears to be a suitable candidate to be used in combination with the more recently developed diaminopyrimidines such as baquiloprim.
Rátz
V
V
Department of Pharmacology and Toxicology, University of Veterinary Science, Budapest, Hungary.
Maas
R
R
Semjén
G
G
van Miert
A S
AS
Witkamp
R F
RF
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D018592:Cross-Over Studies; D006041:Goats; D007275:Injections, Intravenous; D008297:Male; D012418:Ruminants / Q000378:metabolism*; D013416:Sulfamerazine / Q000097:blood / Q000493:pharmacokinetics*; D013420:Sulfamethoxazole / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics*; D013997:Time Factors
D013420:Sulfamethoxazole; D013416:Sulfamerazine; C048358:sulfatroxazole